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Abstract
Background An increasing number of studies indicate that exercise plays an important role in the overall care of prostate
cancer (PCa) patients before, during and after treatment. Historically, research has focused on exercise as a modulator of
physical function, psychosocial well-being as well as a countermeasure to cancer- and treatment-related adverse effects.
However, recent studies reveal that exercise may also directly inﬂuence tumour physiology that could beneﬁcially affect the
response to radiotherapy.
Methods In this narrative review, we provide an overview of tumour vascular characteristics that limit the effect of radiation
and establish a rationale for exercise as adjunct therapy during PCa radiotherapy. Further, we summarise the existing
literature on exercise as a modulator of tumour perfusion and hypoxia and outline potential future research directions.
Results Preclinical research has shown that exercise can reduce intratumoral hypoxia—a major limiting factor in radiotherapy—by improving tumour perfusion and vascularisation. In addition, preliminary evidence suggests that exercise
training can improve radiotherapy treatment outcomes by increasing natural killer cell inﬁltration in a murine PCa model.
Conclusions Exercise is a potentially promising adjunct therapy for men with PCa undergoing radiotherapy that may
increase its effectiveness. However, exercise-induced tumour radiosensitisation remains to be conﬁrmed in preclinical and
clinical trials, as does the optimal exercise prescription to elicit such effects.

Introduction
Radiotherapy is a cornerstone in the management of cancer
and used to treat a myriad of malignancies, including
prostate. Approximately 50% of all cancer patients receive
radiotherapy during the course of their treatment for either
curative or palliative purposes [1]. Moreover, ~40% of
prostate cancer (PCa) patients aged 65 and above receive
radiotherapy as their primary treatment [2]. Despite ever
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evolving technological advances that allow for more precise
targeting of tumours, treatment resistance and subsequent
disease recurrence pose a signiﬁcant challenge in the ﬁeld of
radiation oncology [3–5].
Approximately 20–39% of patients with localised PCa
treated with external beam radiotherapy experience local
disease persistence and subsequent recurrence with an
increased risk of developing distant metastases [6–8]. The
hypoxic tumour microenvironment (TME) is recognised as
a major limiting factor in the treatment of cancer and is an
established prognostic marker that has been associated with
treatment resistance as well as local disease persistence and
recurrence [9, 10]. Moreover, hypoxia is a common feature
of many solid tumours, including PCa [11].
While exercise has been associated with a reduced risk of
PCa progression and mortality [12], little is known about
the underlying biological mechanisms contributing to these
beneﬁts. It has been postulated that exercise may acutely
reduce tumour hypoxia through increased perfusion of
tumour tissue and that structural adaptations of the tumour
vasculature in response to exercise training may potentially
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result in a less aggressive tumour and further enhance
treatment response [13].
Given the signiﬁcance of hypoxia in compromising
cancer treatment, the purpose of this narrative review is to:
(1) provide an overview of the characteristics of tumour
vasculature and how they affect tumour hypoxia; (2)
establish a rationale for exercise as adjunct therapy during
cancer treatment; (3) summarise the existing literature on
exercise as a modulator of tumour perfusion and hypoxia;
and (4) outline potential future research directions.

Tumour vasculature and hypoxia
Angiogenesis is a normal physiological process that occurs
in situations like wound healing or in response to exercise
training [14, 15]. In tumours, however, rapid proliferation of
cells results in the formation of hypoxic areas and subsequent persistent local and unbalanced expression of proand anti-angiogenic factors leads to the formation of dysfunctional and structurally abnormal vascular networks,
which are a characteristic feature of the TME [16]. These
vascular networks are often very disorganised, tortuous and
immature, which results in heterogeneous and variable
tumour blood ﬂow, further aggravating rather than alleviating hypoxia [17, 18]. Consequently, hypoxic and thus
angiogenic signalling are sustained, further driving abnormal tumour vascularisation. In addition, tumour blood
vessels are leakier than normal blood vessels, resulting in
increased interstitial ﬂuid pressure (IFP) [19]. Increased IFP
can lead to sudden, intermittent perfusion changes as a
result of collapsing blood vessels, which, in turn, limits
oxygen delivery to the tumour, further worsening tumour
hypoxia and decreasing treatment efﬁcacy [20]. Moreover,
increased vascular permeability plays a key role in metastasis by facilitating intravasation of cancer cells [21].
Hypoxia arising from vascular abnormalities can be
differentiated into two forms—chronic and acute [22, 23].
Chronic hypoxia arises when the distance between blood
vessels and tumour cells surpass the diffusion distance of
oxygen. Chronic hypoxia is therefore also known as
diffusion-limited hypoxia. When oxygen diffuses from
blood vessels into the adjacent tissue it is consumed by the
tumour cells closest to the perfused vessel, creating a gradient in the partial pressure of oxygen (PO2). The decrease
in PO2 with increasing distance from the perfused vessel
renders tumour cells further away from this vessel more
hypoxic. Acute hypoxia, on the other hand, is caused by
limited and varying perfusion of blood vessels supplying
tumour cells (i.e. perfusion-limited hypoxia). As a result, all
cells that are normally supplied by a now transiently compromised blood vessel are temporarily, or acutely, hypoxic.
The reasons for acutely limited perfusion are numerous and

include occlusion of vessels with blood or circulating
tumour cells, collapse of vessels due to high IFP, and
spontaneous vasoconstriction in normal tumour vessels that
then affect downstream tumour vessels [22, 23]. In addition
to poor tumour perfusion and oxygen diffusion, anaemia is
a further major cause of tumour hypoxia (i.e. anaemic
hypoxia) that results from cancer- and treatment-associated
reduced oxygen transport capacity of the blood [24, 25].
With decreasing tissue oxygen levels, tumour cells
become increasingly resistant to ionising radiation due to
reduced availability of oxygen to stabilise DNA strand
breaks caused by radiation and reactive oxygen species
[23, 26]. In PCa, hypoxia is associated with a more
aggressive tumour phenotype, increased metastasis, and
patients with more hypoxic tumours have a poorer prognosis compared to patients with a less hypoxic TME [27].
Milosevic et al. [28] directly measured tumour hypoxia with
a transrectal needle-electrode technique in 247 patients with
localised PCa before radiotherapy and found that hypoxia
was associated with early biochemical failure and local
disease recurrence. Intrinsic markers of tumour hypoxia (i.e.
hypoxia-inducible factor 1-alpha) have also been investigated and increased expression identiﬁed patients with
shorter time to biochemical failure independent of clinical
tumour stage, biopsy Gleason score, serum prostate-speciﬁc
antigen concentration, and radiotherapy dose [29]. Targeting and reversing tumour hypoxia thus has been proposed
as a potential mechanism to improve treatment response to
radiotherapy and enhance survival [27].
Pharmacological interventions aimed at inducing vascular normalisation to improve treatment efﬁcacy through
increased drug delivery and tumour oxygenation have primarily focused on suppressing vascular endothelial growth
factor (VEGF) signalling given its key role in angiogenesis
[30]. Anti-angiogenic (or anti-VEGF) therapy, originally
developed to disrupt a tumour’s blood supply and deprive it
of oxygen and nutrients, has shown some promise in normalising tumour vasculature when given in low doses, but
has thus far not been tested in prospective clinical trials to
permit concrete conclusions [30, 31]. Furthermore, tumour
vascular normalisation has a small therapeutic window, is
complicated by tumour heterogeneity, and associated with
signiﬁcant side effects as well as malignant progression
[32–35]. Hence, the use of pharmacological angiogenesis
inhibitors has not gained wide clinical application. On the
other hand, mild hyperthermia is increasingly being
explored as a radiosensitiser for its effects on tumour vasculature and DNA repair mechanisms [36]. Relatively
low temperatures of 39–42 °C have been shown to increase
tumour perfusion, thus decreasing hypoxia and enhancing
tumour radiosensitivity [36]. In a recent study using an
orthotopic PCa mouse model, hyperthermia signiﬁcantly
slowed tumour growth and resulted in signiﬁcantly smaller
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Fig. 1 Potential tumour
physiology at rest (left side)
and during exercise (right
side). a Acute exercise increases
tumour blood ﬂow and tumour
vascular resistance is reduced.
b Augmented tumour perfusion
pressure as a result of increased
tumour blood ﬂow may lead to
greater oxygen (O2) diffusion
distance and thus reduce
diffusion-limited hypoxic
tumour areas. c Tumour
vasculature is dysfunctional and
structurally abnormal, resulting
in heterogeneous and variable
tumour blood ﬂow. Exercise
increases the area of tumour
perfusion and therefore reduces
perfusion-limited hypoxia.
Created with BioRender.com.

normalised nadir tumour volumes compared to radiotherapy
without hyperthermia [37]. Similar to anti-VEGF therapy,
though, the timing and dosing of hyperthermia to achieve
the desired radiosensitising effect is complex and makes
clinical application challenging [36].

Exercise as adjunct therapy in cancer
treatment
In the ﬁeld of exercise oncology, i.e. the application of
exercise as medicine in the oncology setting, there is consistent evidence that greater levels of physical activity,
commonly deﬁned as ‘any bodily movement produced by
skeletal muscles that results in energy expenditure’ [38], are
associated with a lower risk of developing certain types of
cancer as well as decreased all-cause and cancer-speciﬁc
mortality for patients diagnosed with breast, colorectal, or
PCa [39]. For example, Kenﬁeld et al. [40] found that men
with PCa who did ≥3 h/week of vigorous physical activity
had a 49% lower risk of all-cause mortality and a 61%
lower risk of dying from PCa compared to men who did <1
h/week of vigorous physical activity. Furthermore, Richman
et al. [41] reported that men with localised PCa who walked

at a brisk pace for ≥3 h/week had a 57% lower risk of
disease progression compared to men who walked at an
easy pace for <3 h/week. This association between walking
pace and reduced risk of cancer progression was independent of walking duration [41], suggesting that not only the
volume of physical activity but also the intensity of physical
activity is an important factor regarding clinical outcomes in
PCa. It is important to note, however, that these ﬁndings are
based on observational data and randomised controlled
trials are currently investigating the impact of exercise on
overall survival in patients with PCa as well as colon cancer
[42, 43].
In addition to reduced risk of disease progression and
mortality, physical activity and exercise, deﬁned as ‘a
subset of physical activity that is planned, structured, and
repetitive and has as a ﬁnal or an intermediate objective the
improvement or maintenance of physical ﬁtness’ [38], are
increasingly being recognised as an important part of
treatment during active therapy to improve or maintain
physical function and quality of life in cancer patients [44].
Research has consistently demonstrated that exercise
improves physical and mental health in men with PCa
during and following completion of therapeutic interventions and can reduce the level of fatigue experienced by
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Fig. 2 Potential mechanism of
exercise-modulated tumour
perfusion and hypoxia.
Systemic effects of augmented
cardiac output and increased
arterial pressure resulting from
mild hyperthermia and increased
stroke volume and heart rate in
response to acute exercise (top
panel) may inﬂuence local
physiological responses and
vascular adaptation in the
tumour microenvironment
(bottom panel). Improved
tumour perfusion, either as a
result of increased systemic
blood ﬂow during exercise or as
a result of vascular maturation,
may enhance acute and chronic
oxygenation of hypoxic tumour
areas, thus resulting in improved
radiotherapy efﬁcacy.

Exercise

Stroke volume
(increased)

Mild hyperthermia

Heart rate
(increased)

Cardiac output
(increased)

Systemic
effect
Arterial pressure
(increased)

Vasodilation

Tumour perfusion
(increased)

Vascular shear stress
(increased)

Tumour perfusion
pressure
(increased)

Vascular maturation

Acute
response

Chronic
adaptation

O2 diffusion distance
(increased)

Tumour
microenvironment

Reduced diffusionlimited hypoxia

Hypoxia
(decreased)

many patients [45–48]. Some studies have also indicated
that exercise may help alleviate toxicities associated with
treatment [49, 50].
More recently, the role of exercise as an adjunct therapy
to enhance the effectiveness of conventional cancer treatments such as radiotherapy is gaining a strong interest for
its effects of modulating tumour vasculature and oxygenation [51, 52]. Potential tumour physiological responses to

O2 delivery
(increased)

Reduced perfusionlimited hypoxia

exercise are shown in Fig. 1. However, mechanistic insight
regarding the beneﬁts of exercise on cancer biology is
currently limited. Acute exercise bouts as well as exercise
training are characterised by distinct physiological responses and result in speciﬁc immediate and chronic adaptations.
It is well established that exercise leads to vascular adaptations in humans [53]. For example, exercise training
improves oxygen delivery to peripheral tissues through

NA

NA

↑ survival vs. anaesthesia; ↓ disease
progression vs. anaesthesia; ↑ tumour
response vs. anaesthesia; ↑ tumour growth
inhibition vs. anaesthesia
NA

↑ perfusion (~200%) vs. rest; ↓ vascular
resistance (~65%) vs. rest; ↑ average
number of patent vessels vs. rest; ↓
hypoxia (~50%) vs. rest
↑ radionuclide uptake vs. anaesthesia; ↑
homogeneity of infection distribution vs.
anaesthesia; ↓ average infection voids vs.
anaesthesia
Forced treadmill running at 15 m/min
↑ perfusion (~181%) in orthotopic tumour
for 5 min
vs. rest; ↓ perfusion (~25%) in ectopic
tumour vs. rest
Forced treadmill running at 10 m/min
↔ doxorubicin levels in tumours vs.
for 45 min
control
↓ hypoxia for high intensity vs. control; ↔
Forced treadmill running at either 6 m/
min (low), 12 m/min (moderate) or 18 m/ hypoxia for low and moderate intensity vs.
no exercise
min (high intensity) for 30 min

NA

vascular remodelling, namely angiogenesis and arteriogenesis [54, 55]. The same structural remodelling of the vasculature in response to exercise may also take place in
tumours, thus potentially improving oxygenation in the
same way it does in working muscles during and after
exercise. Moreover, under acute exercise conditions,
mechanical forces exerted on vessel walls increase with
increasing exercise intensity and are thought to promote the
development of functional mature vasculature [56, 57].
Translated to dysfunctional tumour vasculature, exercise
may result in the development of more mature and less
permeable blood vessels that function more normally. Furthermore, increased heart rate and stroke volume during
exercise result in augmented cardiac output and increase
systemic blood ﬂow, potentially also enhancing perfusion of
tumour tissue. Together with increased tumour blood ﬂow
as a result of vasodilation mediated by mild hyperthermia
that may occur during exercise and increases in mean
arterial pressure that could result in an increased oxygen
diffusion distance within the tumour, there are several
potential exercise-related mechanisms that may alleviate
tumour hypoxia and therefore enhance treatment response
to radiotherapy (Fig. 2).

Lønbro et al. [68]
(Abstract)

Schadler et al. [67]

Exercise modulation of tumour perfusion
and hypoxia

↑ increased, ↓ decreased, ↔ unchanged/no difference, NA not assessed.

Exercise vs. no
exercise (control)
Exercise vs. no
exercise (control)

Exercise vs. rest

Female C57BL6/KaLwRij mice with
5TGM1 myeloma tumours and female
BALB/c mice with MPC11 myeloma
tumours
Male Copenhagen rats with Dunning
R3327-MatLyLu prostate
adenocarcinoma
C57BL/6J mice with B16F10 melanoma
tumours
Female CDF1 mice with C3H mammary
carcinoma
Miller et al. [66]

Garcia et al. [65]

Male Copenhagen rats with Dunning
R3327-MatLyLu prostate
adenocarcinoma
McCullough et al.
[64]

Exercise vs.
anaesthesia

Forced treadmill running at 15 m/min
(10° incline) for 5 min (perfusion
measurements) or 60 min (hypoxia
measurements)
Forced treadmill running at up to 20 m/
min for 20 min
Exercise vs. rest

Tumour model
Author (reference)

Table 1 Acute effects of exercise on tumour perfusion and hypoxia.

Results
Exercise
Intervention

Treatment outcome

Exercise modulation of tumour perfusion and hypoxia to improve radiotherapy response in prostate cancer

As detailed above, physical activity has been associated
with a reduced risk of PCa progression and mortality
[40, 41]. However, little is known about the underlying
biological mechanisms that delay progression and improve
survival in PCa patients. Potential mechanisms have been
summarised by Galvão et al. [58] and include, among
others, changes in tumour vascularisation that may permit
better drug delivery and oxygenation of the tumour through
improved perfusion [58]. Indeed, tumour vessel morphology has been associated with survival outcomes in men
diagnosed with PCa. Mucci et al. [59] evaluated whether
tumour microvessel morphology would predict PCa mortality among 572 men in the prostatectomy cohort of the
Health Professionals Follow-up Study. While greater
microvessel density (MVD) was associated with extraprostatic extension it was not a predictor of mortality in this
analysis. However, the authors found that men with tumours
containing the smallest (area and diameter) and most irregularly shaped vessels had a ~6 times and ~17 times higher
likelihood of developing lethal PCa, respectively.
In a further investigation, also based on data from the
Health Professionals Follow-up Study, Van Blarigan et al.
[60] examined whether physical activity was associated
with tumour vessel morphology in men with PCa.
They found that men who reported a brisk walking pace
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of ≥4.8 km/h had larger, more regularly shaped blood vessels compared to men who reported walking at <4.8 km/h.
However, there was no association between brisk walking
and MVD, and the duration of physical activity (vigorous
and non-vigorous) was not associated with tumour blood
vessel size, shape or number [60].
In the following sections, we discuss the clinical and
preclinical work that has been done to further shed light on
potential mechanisms and how they might affect treatment
outcomes. These sections are not intended to be an
exhaustive review of the relevant literature that examine
exercise as an adjunct therapy in cancer or a means to
improve treatment outcomes. Rather, they are intended
to provide an extensive overview of the efﬁcacy of exercise
to modulate tumour vasculature, perfusion and hypoxia as
well as how these adaptations might translate to improved
treatment outcomes. A literature search was conducted in
Embase, MEDLINE and PubMed using the search terms
exercise AND (cancer OR tumour) AND (perfusion OR
blood ﬂow OR hypoxia OR oxygen OR vascularity OR
vascular OR vessels) as well as exercise AND prostate
cancer AND (radiotherapy OR radiation), and last updated
in February 2020.

Preclinical studies
Aerobic exercise has been linked to a reduction in tumour
incidence, growth and metastasis across a variety of preclinical tumour models. However, meaningful comparisons
and conclusions from current evidence is limited due to
considerable heterogeneity in the methods used across different studies [61]. It has been proposed that exercise can
directly impact tumour physiology and improve anti-cancer
treatment efﬁcacy, thus highlighting the potential of exercise to control disease progression [62]. One
important mechanism by which exercise may govern these
processes is modulation of tumour vascularisation and
perfusion [63].
Acute exercise responses
Compared with short- as well as long-term exercise training
interventions, few studies have investigated how an acute
bout of exercise may affect tumour physiology (Table 1).
Using a preclinical PCa model, McCullough et al. [64]
published the ﬁrst study to investigate tumour blood ﬂow
in vivo during exercise. The authors demonstrated that
compared to resting conditions, exercise comprised of
forced treadmill running signiﬁcantly increased tumour
blood ﬂow by ~200% as well as the number of perfused
blood vessels, with hypoxia decreased by ~50%. These
results were later replicated by Garcia et al. [65], who used a
similar exercise protocol in a PCa model and demonstrated

that exercise increased tumour blood ﬂow by ~180%
compared to resting conditions. Interestingly, this response
was only observed in orthotopic tumours mimicking the
physiological conditions of primary cancers. Ectopic
tumours, which could be regarded as metastatic lesions,
showed a decrease in blood ﬂow of ~25% in response to
exercise.
Miller et al. [66] and Schadler et al. [67] used radionuclide uptake and intratumoral doxorubicin levels as surrogate markers for tumour perfusion, respectively. Whereas
Miller et al. [66] found an increased concentration of
radiotracers with high-intensity exercise compared to a
hypotensive low-perfusion state induced by anaesthesia,
Schadler et al. [67] found no difference in doxorubicin
levels after low-intensity exercise compared to mice not
undergoing exercise. Despite exercising for more than twice
the amount of time (45 vs. 20 min), the mice in the
experiment by Schadler et al. [67] only exercised at half the
intensity (10 vs. 20 m/min), which likely resulted in overall
lower mean arterial pressure compared to the experiment by
Miller et al. [66] and therefore could have resulted in lower
tumour perfusion pressure and hence lower tumour blood
ﬂow. Indeed, preliminary data from Lønbro et al. [68]
suggest that it is only high-intensity exercise and not low- or
moderate-intensity exercise that results in decreased intratumoral hypoxia.
The studies by McCullough et al. [64] and Garcia et al.
[65] both also investigated in vitro vascular responsiveness to norepinephrine. In tumour arterioles, vasoconstriction was blunted by approximately 95% compared
with control prostate vessels [64], and although there was
no difference in vasoreactivity between orthotropic and
ectopic tumours, vasoconstriction was severely reduced
compared with host prostate tissue from healthy control
animals [65]. This blunted vascular responsiveness is
potentially what allows tumour perfusion to be either
maintained or increased during exercise, when blood
would otherwise normally be diverted away from internal
organs to working muscles. Importantly, the resulting
increase in tumour blood ﬂow may play a critical role in
improving oxygenation for radiotherapy as well as
tumour-targeting drug delivery. Additionally, it has been
proposed that acute systemic effects of exercise in combination with increased tumour perfusion may contribute
to slower tumour progression [62]. However, it is currently unknown for how long after exercise these changes
in tumour perfusion last and hence when the optimal time
would be to exercise in relation to treatment, or at which
point there is no added beneﬁt of exercise. Furthermore, it
is unclear what exercise prescription in terms of intensity
and duration would provide the most potent stimulus that
is both feasible and produces a clinically meaningful
response.

Intervention

Buss et al. [72]

Forced treadmill running at 20 m/
min for 60 min/day for 5 days/
week for 35 weeks
As above (see Faustino-Rocha
et al. [87])
Forced treadmill running at 10 m/
min (for melanoma tumour-bearing
mice) or 12 m/min (for PDAC
tumour-bearing mice) for 45 min/
day for 5 days/week for up to
21 days
Voluntary wheel running

Exercise vs. sedentary control

As above (see Faustino-Rocha
et al. [87])
Exercise vs. no exercise (control)

Voluntary wheel running (i.e.
intermittent periods of highintensity, short-duration exercise
with low resistance) for 18 days

Forced treadmill running at
gradually increasing speeds
(20–40 m/min) at a 5% grade for 3
h or until volitional fatigue on
every day for 5–14 days
Forced treadmill running at
gradually increasing speeds up to
17 m/min for 30 or 2 × 30 min
(with 15 min rest) for 10 days
Voluntary wheel running (i.e.
intermittent periods of highintensity, short-duration exercise
with low resistance) for 44 ± 3 days
Voluntary wheel running (i.e.
intermittent periods of highintensity, short-duration exercise
with low resistance) for 8 weeks
Forced treadmill running at 15 m/
min (15° incline) for 60 min/day
for 5–7 weeks

Exercise

Exercise vs. sedentary control

Exercise vs. sedentary control

C57BL/6 ApoE−/− mice with E0771 High vs. low muscular COX-IV
mammary adenocarcinoma
expression

Female Sprague-Dawley rats with
mammary tumours induced by Nmethyl-N-nitrosourea
Faustino-Rocha
As above (see Faustino-Rocha
et al. [88]
et al. [87])
Schadler et al. [67] C57BL/6J mice with B16F10
melanoma tumours or PDAC-4662
pancreatic ductal adenocarcinoma

Faustino-Rocha
et al. [87]

Female BALB/c mice with 4T1
mammary carcinoma and C57BL/6
mice with E0771 mammary
adenocarcinoma

Exercise vs. sedentary control
Male Copenhagen and Nude rats
with Dunning R-3327 AT1 prostate
adenocarcinoma

McCullough et al.
[76]

Betof et al. [71]

C57BL/6 male mice with TRAMPC1 prostate adenocarcinoma

Jones et al. [69]

Exercise vs. sedentary control

Athymic homozygous female mice
with MDA-MB-231 mammary
adenocarcinoma

Jones et al. [70]

Exercise vs. no exercise (control)

Male BALB/c with Dalton’s
lymphoma tumours

Verma et al. [79]

Preclinical studies
Zielinski et al. [86] Female BALB/cByJ mice with EL-4 Exercise vs. sedentary control
lymphoma tumours

Author (reference) Tumour model/patient population

Treatment outcome

NA

NA
↓ tumour growth with exercise +
chemotherapy vs. chemotherapy alone; ↑
DNA damage with exercise +
chemotherapy vs. chemotherapy alone

↔ vascularisation vs. control
↔ MVD vs. control; ↑ number of long
vessels vs. control; ↑ average vessel
length vs. control; ↑ number of visible
lumens vs. control; ↑ lectin-positive
(functional) vessels (24%) vs. control

↔ perfusion vs. low muscular COX-IV NA
expression; ↓ hypoxia vs. low muscular
COX-IV expression

↑ apoptosis vs. control; ↓ tumour growth
rate with exercise + chemotherapy vs.
chemotherapy alone; ↔ tumour growth
rate with exercise only vs.
chemotherapy only

NA

NA

NA

↓ microvascular PO2 variance during
measurement vs. control; ↑
microvascular PO2 (~100%) vs. control;
↔ number of patent vessels; ↓ hypoxia
vs. control; ↓ vasoconstriction vs. nontumour-bearing sedentary control; ↔
vessel contractile function vs. tumourbearing sedentary control
↑ MVD vs. control; ↑ vessel maturity vs.
control; ↑ viable tumour area containing
pericyte-covered vessels and vessel area
covered by pericytes vs. control; ↑
perfusion vs. control; ↓ hypoxia
(~50%) vs. control
↑ MVD vs. control

↑ mean number of perfused vessels vs.
control; ↑ percentage of perfused total
tumour area vs. control; ↑ hypoxia of
total tumour area vs. control
↑ hypoxia vs. control; ↑ perfusion vs.
control; ↑ perfusion homogeneity vs.
control; ↑ vascularisation

↓ size and branching of blood vessels vs. NA
control; ↑ oxygenation vs. control

NA
↓ blood vessel density (25–50%) vs.
control; ↓ blood vessel density over time
in both groups

Results

Table 2 Effects of exercise training on tumour vasculature, hypoxia and treatment outcomes in preclinical and clinical studies.
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Neoadjuvant chemotherapy vs.
neoadjuvant chemotherapy plus
aerobic exercise training
Exercise during preoperative
chemo- or chemoradiotherapy vs.
historical controls (no exercise)

Results

Cycling 3 days/week at 60–100%
of VO2 peak for 30–45 min/session
on a stationary cycle ergometer
Home-based, moderate-intensity
exercise for at least 120 min/week
(prescribed; 60 min aerobic
exercise and 60 min strengthening
exercises)

Forced treadmill running at 18 m/
min (10% incline) with gradually
increasing duration (25–60 min/
day) for 5 days/week for 2 weeks

↑ tumour growth inhibition with exercise
+ doxorubicin vs. doxorubicin alone

Treatment outcome

NA
↓ tumour blood ﬂow (38%; exercise
group); ↔ MVD (between groups); ↔
tumour hypoxia (between groups)
↑ number of vessels (100%) vs. control; NA
↑ MVD vs. control; ↑ number of
elongated vessels vs. control; ↑ number
of open lumens vs. control

↓ time to tumour regression (no palpable
tumour) with exercise + gemcitabine vs.
gemcitabine alone; ↑ time to tumour
recurrence with exercise + gemcitabine
vs. gemcitabine alone
↑ vascularisation with radiotherapy and ↓ tumour volume and weight with
exercise, radiotherapy and radiotherapy
exercise plus radiotherapy vs. control
plus exercise vs. control; ↓ tumour cell
and exercise only; ↔ vascularisation
proliferation with exercise, radiotherapy
with exercise only vs. control; ↔
vascularisation with radiotherapy plus
and radiotherapy plus exercise vs. control;
exercise vs. radiotherapy only; ↑ natural ↑ apoptosis with exercise plus
killer cell inﬁltration and activation with radiotherapy and radiotherapy alone vs.
exercise plus radiotherapy and
exercise only and control; ↑ apoptosis
radiotherapy alone vs. exercise only and with exercise plus radiotherapy vs.
control; ↑ natural killer cell inﬁltration radiotherapy alone
and activation with exercise plus
radiotherapy vs. radiotherapy alone

Forced treadmill running at 12 m/ ↔ tumour vessel morphology (open
lumens, total vessels, MVD, number of
min for 45 min/day for 5
consecutive days/week for 2 weeks elongated vessels) vs. control; ↓
hyperpermeability vs. control; ↓ hypoxia
vs. control; ↑ doxorubicin levels in
tumours vs. control
Forced treadmill running at 12 m/ ↑ tumour vascularity (number of vessels,
open lumens, elongated vessels) vs.
min for 45 min/day for 5 days/
control; ↑ percentage of lectin-positive
weeks for 4 weeks
(functional) vessels vs. control (p = ns)

Exercise

↑ increased, ↓ decreased, ↔ unchanged/no difference, COX-IV cytochrome c oxidase subunit 4, DNA deoxyribonucleic acid, MAP mean arterial pressure, MVD microvessel density, NA not
assessed, PDAC pancreatic ductal adenocarcinoma, PO2, partial pressure of oxygen, VO2 peak volume of peak oxygen uptake.

Florez Bedoya
et al. [77]

Women with operable stage II/III
breast cancer (n = 20) receiving
ﬁrst-line neoadjuvant chemotherapy
PDAC patients (n = 36) receiving
preoperative chemotherapy or
chemoradiotherapy

Male athymic nude mice with PPC-1 Exercise vs. radiotherapy vs.
prostate tumours
exercise plus radiotherapy vs. no
exercise (control)

Dufresne et al.
[80]

Clinical studies
Jones et al. [81]

Female Nude mice with PDAC
patient-derived xenograft

Florez Bedoya
et al. [77]

Exercise vs. no exercise (control)

Male Nude mice with A673 or TC71 Exercise vs. no exercise (control)
Ewing sarcoma

Intervention

Morrell et al. [78]

Author (reference) Tumour model/patient population

Table 2 (continued)
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Adaptations to exercise training
Several animal model studies, predominantly in lymphoma,
breast and PCa, that investigated the effect of exercise
training on tumour physiology, including vascular function
and hypoxia, also assessed tumour growth. In studies by
Jones et al. [69, 70], tumour growth rate was comparable
between exercise groups who had voluntary access to a
running wheel and non-exercising control groups. On the
other hand, exercise signiﬁcantly reduced tumour growth in
a murine breast cancer model [71]. Buss and Dachs [72]
also found that voluntary wheel running slowed tumour
growth rate in hyperlipidemic mice. However, this was only
the case for mice with high muscular cytochrome c oxidase
subunit IV (COX-IV) expression (a biomarker used for the
level of exercise), suggesting that only mice with higher
exercise volumes experienced a reduction in tumour growth
rate [72]. Moreover, exercise appeared to suppress the formation and growth of metastases in exercising animals
[69, 72]. The anti-metastatic effect of exercise may be
linked to its ability to alter vascular permeability through
modulation of redox-sensitive small GTPase activity,
thereby preventing cancer cells from easily crossing the
vessel wall, making it more difﬁcult to establish metastatic
sites [73]. Indeed, studies by Wolff et al. showed that
running distance was inversely correlated with activation of
the redox-sensitive small GTPase Rho [74], and that exercise maintained blood–brain barrier integrity, thus preventing tumour cells from extravasating into the brain [75].
An overview of the studies investigating the impact of
exercise training on tumour vasculature in an attempt to
alleviate hypoxia and improve treatment response are presented in Table 2. Both short-term and long-term exercise
training, in the form of voluntary wheel running or forced
treadmill running, appear to improve intratumoral vasculature. However, while changes in vessel number and size
as well as MVD are inconsistent, ﬁndings of increased
vessel maturity and function that allow for tumours to be
perfused more uniformly and thus increase microvascular
PO2 are more conclusive. Schadler et al. [67] postulated that
increased shear stress exerted on endothelial cells during
aerobic exercise plays an important role in the remodelling
of tumour blood vessels, allowing for greater blood ﬂow to
the tumour. In addition, McCullough et al. [76] found that
temporal variations in microvascular PO2 were reduced in
exercise-trained animals compared to sedentary control rats
in an orthotopic PCa model. Studies have also shown that
the number of patent and perfused vessels increased after
exercise training, resulting in a larger percentage and less
heterogeneously perfused tumour area [67, 69, 70, 77].
These changes in vascularisation and improvements in
perfusion were accompanied by a reduction in tumour
hypoxia [71, 72, 76, 78, 79], and mice with high COX-IV

expression had signiﬁcantly lower levels of hypoxia compared to mice with low levels of COX-IV expression [72].
Effect of exercise on radiotherapy treatment response
To date, only one study has investigated the effect of
exercise in combination with radiotherapy on treatment
outcomes [80]. Dufresne et al. injected human PCa PPC-1
cells subcutaneously into male athymic nude mice and
subjected them to exercise 5 days/week for 25–60 min/day
over 2 weeks in combination with a total of 20 Gray (Gy)
fractionated into four doses of 5 Gy each. Mice were randomised to either no exercise (control), exercise only,
radiotherapy only, or exercise plus radiotherapy. In contrast
to previous studies, exercise alone did not increase tumour
vascularisation; however, radiotherapy (with or without
exercise) did. Radiotherapy further caused an increase in
natural killer cell inﬁltration and activity that resulted in
increased tumour cell apoptosis. Interestingly, this response
was potentiated when exercise was combined with radiotherapy [80]. These results are exciting and provide preliminary preclinical evidence on the application of exercise
as an adjunct therapy during radiotherapy in PCa.

Clinical studies
Despite the large number of clinical studies in the ﬁeld of
exercise oncology and although preclinical studies have
produced promising results, very few clinical studies have
actually investigated the effect of either an acute bout of
exercise or prolonged exercise training on tumour vasculature, perfusion and hypoxia in humans. To our knowledge, only two studies have been conducted in a clinical
population [77, 81] (Table 2). Jones et al. [81] performed a
pilot study where they allocated 20 women with operable
breast cancer receiving neoadjuvant chemotherapy to either
chemotherapy alone or chemotherapy plus aerobic exercise
training, consisting of thrice weekly cycling on a stationary
ergometer at 60–100% of peak oxygen consumption for
30–45 min/session. At baseline and after 9 weeks of the
intervention (i.e. after three cycles of chemotherapy),
tumour blood ﬂow was assessed using 15O-labelled water
positron emission tomography (PET). In the exercise group,
tumour blood ﬂow decreased by an average of 38%.
However, the analysis was limited by the fact that pre/post
PET scans were only available for ﬁve women in the
exercise group (for two women in the control group for
whom pre/post PET scans were available data were not
reported). Further immunohistochemical analysis of tumour
biopsies at the same time point (i.e. after 9 weeks of the
intervention) revealed no difference between groups in
relation to markers of hypoxia and MVD. However, similar
to the PET assessment, tissue samples were only available
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for a small number of patients due to pathologic complete
response rates to chemotherapy treatment.
In contrast, Florez Bedoya et al. [77] assessed tumour
vessel morphology in tissue samples from 23 pancreatic
ductal adenocarcinoma patients participating in an exercise
intervention during preoperative chemo- or chemoradiation
therapy and compared them to 13 historical controls (i.e.
tumour samples from patients not undergoing exercise prior
to surgery). The authors reported that 2 h/week of prescribed home-based exercise training resulted in remodelling of the tumour vasculature. Speciﬁcally, the total
number of vessels, the number of elongated vessels, MVD
as well as the number of open vessel lumens were all
increased in samples from the exercise group compared
with control samples. In theory, these vascular adaptations
could result in improved chemotherapy and/or oxygen
delivery to the tumour and hence improve clinical outcomes. However, further clinical studies are warranted to
conﬁrm these results and evaluate the effects of exerciseinduced vascular remodelling on treatment efﬁcacy as well
as long-term outcomes.
Neoadjuvant and pre-surgical settings provide an excellent opportunity to study some of these outcomes. Indeed,
several clinical trials are currently ongoing or have recently
been completed and are pending publication of results,
which will add to this body of knowledge. The majority of
these registered studies are being conducted in PCa patients,
either investigating vascular adaptations in response to
exercise training prior to prostatectomy and subsequently
analysing resected tumour tissue samples for tumour vessel
morphology and hypoxic tumour area as well as intratumoral natural killer cell inﬁltration (ClinicalTrials.gov
Identiﬁer: NCT02954783 and NCT03365076), or investigating changes in tumour perfusion and hypoxia in response
to acute exercise exposure using either magnetic resonance
imaging or by pathological analysis of tumour tissue samples excised during radical prostatectomy (ANZCTR
Registration number: ACTRN12620000432910; ClinicalTrials.gov Identiﬁer: NCT03675529). These studies will
add further information regarding exercise as a potential
modulator of the TME in clinical populations and provide
insight into mechanistic pathways.

Implications for future research
Whereas initial clinical research shows mixed results, preclinical studies indicate that exercise may beneﬁcially alter
tumour physiology. In addition, one study in a PCa mouse
model found that exercise increases the efﬁciency of
radiotherapy, resulting in decreased tumour growth. These
ﬁndings are promising and should encourage further
investigation into this novel area of exercise and PCa

research. However, given the paucity of research to date it is
unclear what exercise prescription would deliver the desired
outcome. Furthermore, speciﬁc tumour characteristics such
as the initial degree of vascularity and metabolism will
likely also inﬂuence outcome measures such as hypoxia and
should be taken into consideration when designing future
studies.
From a physiological perspective, the FITT principles of
training, i.e. frequency, intensity, time (duration) and type
of exercise should be considered as a starting point to formalise structured research questions. Different exercise
intensities and types (e.g. aerobic vs. resistance training) are
associated with distinct biochemical as well as physiological adaptations that may differentially affect tumour physiology. Furthermore, not all frequency schedules will likely
be feasible for a speciﬁc exercise intensity (e.g. daily
exercise at high intensity) and carefully considered periodisation schedules will need to be employed to maintain
exercise tolerability during treatment [44, 82].
A concept that could be particularly interesting in this
setting and patient population is the ‘minimal dose
approach’ to exercise [83]. Considering the busy appointment schedule of patients, the minimal effective ‘dose’ of
exercise (in terms of frequency, intensity and duration/time,
or volume) would be extremely valuable to minimise patient
burden. Hence, establishing or disproving dose–response
relationships as well as threshold or ceiling effects will be
essential to facilitate research translation into clinical practice. Similar to pharmaceutical drugs, exercise will likely
also have a therapeutic window, where a certain minimal
‘dose’ is required to produce a desired effect and an upper
tolerable ‘dose’ that will determine what is actually feasible
for patients to safely accomplish.
In addition to the FITT principles of training, the timing
of exercise in relation to treatment is likely to also be of
importance. To achieve an oxygen enhancement effect for
radiotherapy, the timing of exercise (i.e. pre-radiation)
seems crucial, given that cellular oxygen is required at the
time of radiation. Also, a distinction should be made
between acute physiological changes and structural vascular
adaptations that may aid treatment delivery and improve
efﬁcacy, including the time course in which these will
likely occur.
From a clinical point of view, safety and efﬁcacy trials in
human populations are warranted. Although exercise is not
a drug, it does drive a myriad of endogenous molecules to
be produced that have inﬂuence locally and systemically as
well as the effects of physical loading on vessels and other
structures causing acute and chronic effects and adaptations.
Therefore, it has been proposed that combining exercise
with conventional cancer treatments should be held to the
same standards as other combination treatments when
evaluating treatment outcomes [84, 85]. Furthermore,
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logistical aspects that may affect the biological response
also need to be taken into account. For example, studies in
PCa patients investigating exercise in combination with
radiotherapy may consider the timing and quantity of ﬂuid
intake before radiotherapy sessions, as gastrointestinal
passage time and thus urine production may be affected by
certain exercise durations and intensities. This may affect
the positioning of the tumour mass due to ﬂuctuating
bladder volumes and ultimately lead to less radiation dose
being delivered to the tumour and cause more toxicity to
surrounding tissues.
Despite these potential challenges of implementing such
trials, they will be a valuable addition to our understanding
of the interaction between exercise and the TME and, if
shown to be effective, will have clinical implications
beyond the PCa population. However, men with PCa may
particularly beneﬁt from these developments, as initial
observations appear to indicate that exercise of at least
moderate intensity is required to elicit beneﬁcial effects (i.e.
increased tumour perfusion and subsequently reduced
hypoxia). Men with PCa are usually relatively asymptomatic with respect to their disease and probably have a
higher exercise capacity than many other cancer groups,
such as pancreatic cancer patients, thus allowing them to
exercise at an intensity to gain a beneﬁt. Furthermore, men
awaiting radical prostatectomy represent an ideal cohort to
study these interactions as it allows researchers to directly
study the impact of exercise on the tumour without the
interference of neoadjuvant treatments and without
having patients undergo additional invasive procedures to
acquire tissue samples required to investigate potential
mechanisms.
Collectively, further research in this area will add to
the understanding of the underlying biological mechanisms of combination treatments involving exercise and
address safety as well as dosing considerations important
to both patients and clinicians. As a ﬁrst important step,
however, studies should address proof-of-concept outcomes such as short- and/or long-term reductions in
tumour hypoxia as well as acute and chronic tumour
perfusion changes as a result of exercise. We suggest
these studies should incorporate non-invasive functional
imaging modalities and immunohistochemical techniques
to monitor tumour responses and pinpoint molecular
mechanisms, with closely deﬁned and reported patient
populations and tumour characteristics as well as exercise
prescription parameters to then develop more targeted
interventions. Potentially, the ﬁndings of these studies
will change best practice in radiation oncology with
patients completing brief exercise bouts immediately (or
shortly) before radiation doses, which may result in
increased therapy success and a greater rate of cancer cure
or delayed disease progression.
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